AR109737A1 - INHIBIDORES DE b-LACTAMASA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS - Google Patents
INHIBIDORES DE b-LACTAMASA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANASInfo
- Publication number
- AR109737A1 AR109737A1 ARP170102682A ARP170102682A AR109737A1 AR 109737 A1 AR109737 A1 AR 109737A1 AR P170102682 A ARP170102682 A AR P170102682A AR P170102682 A ARP170102682 A AR P170102682A AR 109737 A1 AR109737 A1 AR 109737A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- optionally substituted
- oxo
- groups selected
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- -1 -OH Chemical group 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Pyrrole Compounds (AREA)
Abstract
Estos compuestos actúan como inhibidores de b-lactamasa, y sales, formas cristalinas y formulaciones de la misma. En ciertos aspectos, se refiere a métodos para usar tales compuestos en combinación con un antibiótico b-lactámico para tratar infecciones causadas por bacterias Gram-negativas, incluyendo cepas resistentes a fármacos. Reivindicación 1: Un compuesto de la fórmula (1), en donde p es 1 ó 2; R¹ y R² se seleccionan independientemente a partir de H y alquilo C₁₋₄ opcionalmente sustituidos por hasta tres grupos seleccionados a partir de halo, CN, -OR, oxo, y -NRR; Z es NR³ o N-OR³; R³ se selecciona independientemente en cada ocurrencia a partir de H, Cy, y alquilo C₁₋₄ opcionalmente sustituido por hasta tres grupos seleccionados a partir de Cy, halo, CN, -OR, y -NRR; Cy es un anillo de cicloalquilo C₃₋₆ o anillo heterocíclico de 4 - 6 miembros que contiene uno o dos heteroátomos seleccionados a partir de N, O y S como miembros de anillo, y Cy es opcionalmente sustituido por hasta tres grupos seleccionados a partir de oxo, halo, alquilo C₁₋₂, CN, -OR, y -NRR; y R y R se seleccionan independientemente a partir de H y alquilo C₁₋₄ opcionalmente sustituido por uno o dos grupos seleccionados a partir de halo, -OH, -CN, -O-(alquilo C₁₋₄), oxo, -NH₂, -NH(alquilo C₁₋₄), y -N(alquilo C₁₋₄)₂, o R y R tomados junto con el átomo de nitrógeno al que están unidos pueden formar un anillo seleccionado a partir de piperidina, morfolina, pirrolidina, y azetidina, en donde el anillo es opcionalmente sustituido por uno o dos grupos seleccionados a partir de halo, alquilo C₁₋₂, -OH, -CN, -O-(alquilo C₁₋₄), oxo, -NH₂, -NH(alquilo C₁₋₄), y -N(alquilo C₁₋₄)₂; o una sal o forma zwiteriónica del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401022P | 2016-09-28 | 2016-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109737A1 true AR109737A1 (es) | 2019-01-16 |
Family
ID=60191429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102682A AR109737A1 (es) | 2016-09-28 | 2017-09-28 | INHIBIDORES DE b-LACTAMASA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS |
Country Status (41)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190061A1 (ar) | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
| EP3854786A4 (en) | 2018-09-21 | 2022-09-14 | API Corporation | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
| CN115368261A (zh) * | 2022-07-29 | 2022-11-22 | 武汉理工大学 | N-烯丙基-n-苄基-2-(苄基氨基)乙酰胺的合成方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
| CA2143519A1 (en) * | 1994-03-11 | 1995-09-12 | Markus Bohringer | Beta-lactams |
| AU4055697A (en) | 1996-08-16 | 1998-03-06 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP1025228A4 (en) | 1997-10-21 | 2002-09-18 | Human Genome Sciences Inc | HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR |
| CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JP4638876B2 (ja) | 2003-05-23 | 2011-02-23 | ワイス | Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用 |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| JP2007518399A (ja) | 2003-12-02 | 2007-07-12 | ジェンザイム コーポレイション | 肺癌を診断および治療する組成物並びに方法 |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| PT1866339E (pt) | 2005-03-25 | 2013-09-03 | Gitr Inc | Moléculas de ligação a gitr e suas utilizações |
| CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
| AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール， インコーポレイテッド | Ｇｉｔｒ結合分子を使用する併用療法 |
| DK2231667T3 (da) * | 2008-01-18 | 2013-12-16 | Merck Sharp & Dohme | Beta-lactamase-hæmmere |
| HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| WO2010030002A1 (ja) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| ME02505B (me) | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Heterodimerni vezujući proteini i njihove upotrebe |
| ES2606059T3 (es) * | 2011-08-30 | 2017-03-17 | Wockhardt Limited | Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas |
| ES2640520T3 (es) | 2011-09-13 | 2017-11-03 | Wockhardt Limited | Compuestos que contienen nitrógeno y su uso |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| US9025112B2 (en) | 2012-02-02 | 2015-05-05 | Apple Inc. | Display with color mixing prevention structures |
| WO2013122888A2 (en) | 2012-02-15 | 2013-08-22 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| SG11201406120SA (en) | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
| CN104334558A (zh) | 2012-03-30 | 2015-02-04 | 丘比斯特药物股份有限公司 | 1,3,4-噁二唑和1,3,4-噻二唑β-内酰胺酶抑制剂 |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CA2881169C (en) | 2012-08-25 | 2020-06-16 | Wockhardt Limited | 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections |
| WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| IN2013MU03216A (es) * | 2013-10-11 | 2015-07-03 | Wockhardt Ltd | |
| WO2016116788A1 (en) * | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| EP3075381A1 (en) * | 2015-04-03 | 2016-10-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| CN107438614B (zh) * | 2015-04-03 | 2020-01-31 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
| JOP20190061A1 (ar) | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
-
2017
- 2017-06-16 JO JOP/2019/0061A patent/JOP20190061A1/ar unknown
- 2017-09-27 TW TW106133157A patent/TWI746652B/zh active
- 2017-09-28 CR CR20190104A patent/CR20190104A/es unknown
- 2017-09-28 UA UAA201900256A patent/UA123833C2/uk unknown
- 2017-09-28 WO PCT/IB2017/055973 patent/WO2018060926A1/en unknown
- 2017-09-28 TN TNP/2019/000020A patent/TN2019000020A1/en unknown
- 2017-09-28 US US15/718,571 patent/US10065957B2/en active Active
- 2017-09-28 RS RS20200740A patent/RS60483B1/sr unknown
- 2017-09-28 MY MYPI2019000304A patent/MY189632A/en unknown
- 2017-09-28 UY UY0001037424A patent/UY37424A/es unknown
- 2017-09-28 AR ARP170102682A patent/AR109737A1/es unknown
- 2017-09-28 MA MA050427A patent/MA50427A/fr unknown
- 2017-09-28 ES ES20165564T patent/ES2902579T3/es active Active
- 2017-09-28 MD MDE20190874T patent/MD3519419T2/ro not_active IP Right Cessation
- 2017-09-28 JP JP2019516249A patent/JP7094275B2/ja active Active
- 2017-09-28 PE PE2019000446A patent/PE20190459A1/es unknown
- 2017-09-28 ES ES17791737T patent/ES2801874T3/es active Active
- 2017-09-28 LT LTEP17791737.4T patent/LT3519419T/lt unknown
- 2017-09-28 MA MA46356A patent/MA46356B1/fr unknown
- 2017-09-28 CA CA3030373A patent/CA3030373A1/en active Pending
- 2017-09-28 AU AU2017335405A patent/AU2017335405B2/en not_active Ceased
- 2017-09-28 EA EA201990819A patent/EA036675B1/ru not_active IP Right Cessation
- 2017-09-28 ME MEP-2020-111A patent/ME03735B/me unknown
- 2017-09-28 BR BR112019002195-7A patent/BR112019002195A2/pt not_active Application Discontinuation
- 2017-09-28 HU HUE17791737A patent/HUE049788T2/hu unknown
- 2017-09-28 EP EP17791737.4A patent/EP3519419B1/en active Active
- 2017-09-28 US US16/323,668 patent/US10597396B2/en active Active
- 2017-09-28 SI SI201730285T patent/SI3519419T1/sl unknown
- 2017-09-28 PL PL17791737T patent/PL3519419T3/pl unknown
- 2017-09-28 CU CU2019000016A patent/CU24562B1/es unknown
- 2017-09-28 EP EP20165564.4A patent/EP3698796B1/en active Active
- 2017-09-28 SG SG11201900394SA patent/SG11201900394SA/en unknown
- 2017-09-28 MX MX2019003640A patent/MX2019003640A/es unknown
- 2017-09-28 KR KR1020197008487A patent/KR20190058492A/ko active IP Right Grant
- 2017-09-28 PT PT177917374T patent/PT3519419T/pt unknown
- 2017-09-28 DK DK17791737.4T patent/DK3519419T3/da active
- 2017-09-28 CN CN201780060128.9A patent/CN109843894B/zh active Active
-
2019
- 2019-01-09 ZA ZA2019/00137A patent/ZA201900137B/en unknown
- 2019-01-29 CL CL2019000232A patent/CL2019000232A1/es unknown
- 2019-02-15 PH PH12019500331A patent/PH12019500331A1/en unknown
- 2019-02-28 CO CONC2019/0001995A patent/CO2019001995A2/es unknown
- 2019-03-08 EC ECSENADI201916602A patent/ECSP19016602A/es unknown
- 2019-03-26 IL IL265626A patent/IL265626B/en unknown
-
2020
- 2020-06-17 CY CY20201100557T patent/CY1123062T1/el unknown
- 2020-06-19 HR HRP20200986TT patent/HRP20200986T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120269T1 (el) | Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης | |
| DOP2017000310A (es) | Inhibidores de metalo-beta-lactamasa | |
| EA201691766A1 (ru) | Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций | |
| CO2021007242A2 (es) | Composición de control de organismos nocivos y método para usar la misma | |
| PH12019500558A1 (en) | Beta-lactamase inhibitor compounds | |
| AR091222A1 (es) | INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO | |
| AR109737A1 (es) | INHIBIDORES DE b-LACTAMASA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| TN2017000207A1 (en) | Isoxazole hydroxamic acid compounds as lpxc inhibitors | |
| AR104128A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de infecciones bacterianas | |
| EA201591697A1 (ru) | Гидрохлоридные соли антибиотического соединения | |
| EA201990738A1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| AR099825A1 (es) | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas |